Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non Operating Income (2016 - 2025)

Amphastar Pharmaceuticals has reported Non Operating Income over the past 13 years, most recently at -$3.7 million for Q4 2025.

  • Quarterly results put Non Operating Income at -$3.7 million for Q4 2025, down 225.11% from a year ago — trailing twelve months through Dec 2025 was -$16.8 million (down 131.4% YoY), and the annual figure for FY2025 was -$16.8 million, down 511.65%.
  • Non Operating Income for Q4 2025 was -$3.7 million at Amphastar Pharmaceuticals, up from -$3.8 million in the prior quarter.
  • Over the last five years, Non Operating Income for AMPH hit a ceiling of $12.9 million in Q3 2021 and a floor of -$12.6 million in Q4 2023.
  • Median Non Operating Income over the past 5 years was -$1.1 million (2022), compared with a mean of -$607000.0.
  • Biggest five-year swings in Non Operating Income: surged 647.31% in 2023 and later tumbled 4699.25% in 2025.
  • Amphastar Pharmaceuticals' Non Operating Income stood at $3.2 million in 2021, then decreased by 10.74% to $2.9 million in 2022, then plummeted by 543.18% to -$12.6 million in 2023, then surged by 123.36% to $3.0 million in 2024, then tumbled by 225.11% to -$3.7 million in 2025.
  • The last three reported values for Non Operating Income were -$3.7 million (Q4 2025), -$3.8 million (Q3 2025), and -$2.8 million (Q2 2025) per Business Quant data.